favorit smid-cap idea head print
head print wit one largest sell-off smid-cap univers
stock averag qtd russel believ sell-off
macro driven increas interest rate tariff sector fundament chang read-
through indic cardiovascular orthoped spine neurovascular
capit equip end-market track in-lin better expect thu expect
smid-cap univers disappoint
share captur continu recent pull-back qtd creat favor risk/reward
believ expect moder sinc compani report strong august
rais guidanc mid-point howev think lack competit set
multi-year share gainer ambulatori cardiac monitor market continu string
beat rais forecast revenu fce revenu
guidanc vs fce report octob close
us spine market stabil focu manag transit plan gross
margin recent nuva board announc chri barri becom compani next ceo
effect novemb expect portion call focu manag transit
plan think product west carlton hot topic model
revenu fce adjust ep fce manag
guidanc includ revenu rbce vs fce adjust
ep rbce vs fce sold new ceo announc
investor point lack guidanc updat press releas announc leadership chang
believ creat favor risk/reward quarter buyer stock
report octob close
ischem stroke competit concern overblown believ gener revenu
growth next three year driven market lead technolog engin jet
forecast revenu fce adjust ep fce
manag revenu guidanc rbce vs fce investor
concern new competit come believ alreadi reflect
recent pullback confid consensu forecast report novemb
sale forc product augment inject cartiva provid upsid guidanc
new product launch improv sale forc product recent close acquisit cartiva
fuel upsid wmgi revenu guidanc end august manag rais
revenu guidanc rbce vs fce due continu strong demand
shoulder product improv momentum core lower extrem latest guidanc
includ cartiva deal thu expect consensu move higher post earn
call forecast revenu fce adjust ebitda fce
report novemb see upsid low
recent sell-off provid buy opportun earlier month provid busi
updat includ four senhanc sale guidanc includ demo system
preliminari revenu fce also manag announc receiv ce mark
senhanc ultrason instrument receiv fda clearanc instrument
report novemb
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
set-up smid-cap med-tech prior print
ytd smid-cap med-tech one best perform sector healthcar
xhe view believ smid-cap med-tech perform well owe investor
appetit explos top-lin growth faster grow end-market
technolog also help mani smid-cap med-tech compani limit exposur
currenc tariff risk
recent howev wit larg sell-off smid-cap compani
univers qtd russel take fundament
chang due dilig includ doctor day survey attend
major medic confer investor meet non-deal roadshow indic major
end-market cardio ortho spine neurovascular capit equip remain stabl
regard volum price valuat trade slightli
averag believ recent sell-off driven macro factor increas
interest rate investor take profit ahead earn season
last month attend annual north american spine societi nass confer
la take-away confer us spine market appear stabl
sequenti grow low-singl digit y/i attend analyst meet
confer suggest manag team optimist market growth
fuel new technolog navig robot pleas click
in-depth review nass came away nass increment posit
tuck-in within med-tech continu top-lin growth strategi large-cap
smid-cap recent announc deal includ acquir ktwo
acquir mzor acquir cartiva acquir mst medic surgeri
increas ownership stake mvi view smid-cap compani look
innov technolog complement product portfolio meanwhil large-cap
continu focu compani adjac core market leverag
sale market infrastructur creat valu expect tuck-in activ
head quarter favorit smid-cap idea
play ambulatori cardiac monitor market expect
moder sinc compani report strong believ lack
competit set multi-year share gainer expect compani
continu strong track record beat rais
think best posit take share us spine market
think improv product west carlton drive upsid margin ep
sold new ceo announc investor point lack guidanc
updat press releas announc leadership chang believ creat
favor risk/reward quarter
pen ischem stroke market grow next three year believ
continu share gainer driven market lead technolog engin
jet investor concern new competit come
believ alreadi reflect recent pullback
wmgi new product launch improv sale forc product recent close
acquisit cartiva fuel upsid wmgi revenu guidanc
final think recent sell-off provid buy opportun head
print sinc compani alreadi pre-announce result
note irtc averag ev/ begin ipo date
factset price market close
exhibit select smid-cap rbce vs consensu
capit market estim factset op outperform sp sector perform price market close
ev-to-sal ntm basi smid-cap med-tech valuat remain flat compar
one year ago custom market-weight index smid-cap trade ntm compar
one year ago howev multipl recent drop high
believ recent sell-off smid-cap macro driven rather industri specif
fundament creat favor set-up group head earn
price returnforward ev-to-salesforward p/emarket capstock pricestock pricestock pricetick returnytd highytd lowcurr ev/ ev/ lowavg med-tech small cap sept revenuessept epspric targettickerratingrbcey/yconsensusrbcey/yconsensusptupsid ptmedic technolog technolog orthopedic/spine/wound exhibit smid-cap med-tech valuat ev/sal declin recent
capit market estim factset price market close
short interest smid-cap med-tech reach ytd high sept oct
analysi cover latest short interest si releas octob data
septemb octob among smid-cap si float prior
increas driven increas off-set
ktwo past month smid-cap si increas next si
releas date novemb market close
notabl si chang within coverag includ
irtc si increas last two period controversi high-
growth stock continu gain attent short player think compani
reimburs competit risk howev compani technolog superior
competitor would anoth year irtc temporari code would
renew
pen si increas prior period si increas
past three month short player continu bet competit big devic
manufactur slow pen growth stroke sale howev pen
technolog superior competitor recent releas gener
aspir pump engin gener aspir cathet jet compar
favor competit market first second gener system
recogn pen competit consist big devic player bundl
product due dilig suggest physician prefer use technolog
advanc tool less price sensit
tickercompani total short total short interest float i/oday cover changeweight changedxcmdexcom lifesci hold medic inc class group hold smid-cap med-tech stock overview prior earn
expect moder evid
pullback stock qtd
report octob market close august report best
quarter sinc go public revenu beat consensu compani rais
mid-point revenu guidanc revenu
guidanc increas largest step-up sinc compani went public one
could argu set-up somewhat challeng compani post outstand
recent pullback stock creat favor risk/reward buyer
stock
quarter announc new watch fda approv ecg
monitor drove stock intra-day review fda approv
letter conclud new watch compet directli zio
rather bring awar zio servic note dont let watch scare buy dip
believ new watch may broaden awar gener public sinc wearabl
technolog watch alert patient may irregular
heartbeat would lead patient visit cardiologist may prescrib zio
servic diagnost test thu believ expand irtc market would
address group patient may previous reach
forecast revenu in-lin consensu howev given
compani histori beat rais would surpris see compani
beat expect manag guidanc includ revenu
rbce vs fce gross margin rbce vs fce
sg rbce vs fce
investor focu earn call
addit manag provid insight guidanc investor focu
commentari relat competit adopt zio new product
pull zio xt sale manag sale forc hire plan also
expect topic reimburs discuss
us spine market stabil focu
manag transit plan gross margin
report result octob market close
model revenu fce increas y/i adjust ep
fce increas y/i product categori perspect
model us spinal hardwar revenu fce us surgic support
revenu fce puerto rico revenu
manag guidanc includ revenu rbce
vs fce includ expect revenu benefit
safepassag acquisit fx benefit prior manag revenu
guidanc assum organ revenu y/i impli growth
nuva adjust ep rbce vs fce
manag current revenu guidanc impli bp world-wide organ spine market
share gain believ manag guidanc appear achiev new
product launch product recent sale forc add ramp intern
manag remain confid y/i revenu growth continu
manag believ need expand new geograph area
order maintain current intern growth y/i current
intern spine market share part manag strategi doubl
intern busi next five year
recent attend north american spine societi nass confer one
key takeaway us spine market appear stabl sequenti grow low-
singl digit y/i nass note earn call octob learn
continu
slight posit pure-play
manufactur ktwo howev spine perform
improv sequenti second straight quarter saw spine busi grow cc
y/i includ believ market stabil base analysi believ
spine market grew y/i look stabl slightli improv sequenti
lose world-wide spine share
recent nuva board announc current ceo greg lucier step
ceo remain chairman board mr lucier replac chri barri mr barri
join presid surgic innov larger
barri manag employe locat countri new leadership announc
sent share investor express concern quarter outlook
share concern buyer stock pleas click read
recent note nuva leadership chang
look earn call
earn call believ investor focu nuva manag
transit plan separ given ep guidanc lower
prior due lower gm reduc oper margin
guidanc reduc focu statu west carlton facil
recal gross margin soft fce due slower ramp new
manufactur facil howev manag see improv product june
juli give manag confid gross margin
oper margin expand
report novemb forecast ww revenu fce
increas y/i adjust ep fce
believ pen neurovascular segment grow y/i pen peripher vascular
segment grow y/i confid consensu forecast
recent initi coverag note initi coverag outperform rate
believ neurovascular peripher vascular market under-penetrated
well posit take market share due superior product line-up
project revenu growth next three year
announc gener aspir pump engin gener
aspir cathet jet engin provid stronger vacuum easier set-up compar
competitor product jet largest inner diamet inch aspir
cathet market increas aspir lumen size jet lead faster
recan higher
likelihood clot remov success first pass without
compromis safeti believ compar favor competit
market first second gener system
investor focu earn call
think investor focu manag commentari around competit
stroke recent announc launch aspir system riptid
believ riptid inferior pen engin aspir pump addit focu
whether progress made state legisl adjust emerg guidelin
triag transport stroke patient appropri primari stroke center state
alreadi chang legisl includ arizona rhode island tennesse state
current work chang emerg guidelin includ colorado
massachusett new york ohio
sale forc product augment inject
cartiva provid upsid guidanc
report earn novemb end august manag rais
revenu guidanc rbce vs fce
due continu strong demand shoulder product improv momentum
core lower extrem busi guidanc includ cartiva deal
forecast revenu fce increas y/i
adjust ebitda fce
june announc receiv pre-market approv fda augment
inject bone graft indic hindfoot ankl fusion current
augment bone graft pellet form origin launch augment
inject alreadi fda approv canada australia follow introduct
augment inject canada australia augment sale increas expect
augment inject lead re-acceler augment sale prior surgeon
check suggest use pellet form augment add minut case
frustrat particularli arthroscop procedur expect augment inject
increas eas use frequenc use surgeon foot/ankl manag
estim augment commerci opportun alon
recent announc complet acquisit cartiva privat compani
focus treatment osteoarthr great toe manag
expect y/i sale cartiva gener gross margin cartiva
contribut adjust ebitda great toe arthriti
procedur perform annual repres market opportun
channel check suggest cartiva one innov smaller foot/ankl
manufactur note implant price premium fusion
vs fusion howev believ could partial replac first
metatarsophalang mtp joint fusion mtp arthroplasti routin fail surgeon
also note procedur quick easi faster fusion
mtp joint fusion could still perform later implant fail believ mid-teen
revenu growth realist cartiva see stock rise low
investor focu wmgi call
call expect manag rais revenu guidanc includ cartiva
would also like hear statu compani end-market shoulder
foot/ankl due dilig suggest end-market continu grow high-
single-digit also focu manag commentari sale forc product
earn call manag state saw evid sale forc
product overhang manag guid faster
expect sale forc ramp believ improv product sourc upsid
revenu also investor focu manag comment relat
competit landscap given launch zbh stemless shoulder us lastli
look forward compani speak cartiva integr plan
report novemb market close believ last week sell-off
share provid buy opportun sinc compani alreadi pre-announce
thu de-risk print trxc pre-announce includ four system sale
manag guidanc rbce three system revenu fce
robot sale includ one us magee-women hospit pittsburgh
two robot sale emea region emea sale sold distributor one
demonstr system use support territori market regulatori initi
manag also announc receiv clearanc instrument set
file june well addit instrument septemb file
clearanc ultrason instrument system expect achiev fda clearanc
compani receiv ce mark ultrason system expect
commerci launch system ce countri final compani expect
submit applic fda clearanc diamet articul instrument
receiv ce market
recent announc acquir substanti asset mst medic
surgeri technolog ltd mst isra medic technolog compani found
develop software-bas imag analyt platform power advanc
visual scene recognit artifici intellig machin learn data analyt
also acquir mst intellectu properti pend applic
grant patent center israel along team employe
transact expect close
surgic robot launch slip month manag origin
expect believ clear runway next month
driver share next month includ fda approv new instrument
technolog addit senhanc sale earlier year receiv fda approv
two new indic senhanc laparoscop inguin hernia laparoscop
cholecystectomi two new indic commonli perform
procedur us us hospit perform procedur increas
trxc procedur per year base trxc ytd perform
feel confid manag continu deliv commit
investor focu earn call
think regulatori timelin import catalyst particular want
hear confirm articul instrument track file year-end
also expect manag updat us ultrason energi instrument
expect launch europ late
thousand except gross total oper oper incom interest incom incom net incom earn per weight-averag share margin analysi profit analysistot sale sale oper profit exhibit
nuvas quarterli earn million except per share data spinal hardwar surgic support puerto sale market administr oper interest pre-tax tax tax loss attribut non-controlling net average share fulli analysisnon-gaap sale market oper net growthu spinal hardwar surgic support puerto sale market oper pre-tax tax net exhibit
thousand except peripher total gross oper incom interest incom incom provis benefit incom net equiti loss unconsolid net incom common adjust net incom adjust dilut share outstand margin analysisy/i neuro peripher total sequenti dilut exhibit
wright medic group pro-forma incom statement million except per share medicin expens incom incom expens raten/mn/mn/mn/mn/mn/mn/mn/mn/mn/mn/mn/mnet dilut earn per dilut earn per share average dilut share margin analysisupp medicin dilut earn per dilut earn per share exhibit
incom statement thousand except per share oper intang fv cont relat expens incom tax raten/an/an/an/an/an/an/an/an/an/an/an/anet translat net dilut average dilut share analysi analysi total fulli dilut med-tech smid-cap preview
